Shanghai

Who we are

  • July 29, 2024
    HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors
  • January 17, 2024
    A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer
  • January 10, 2024
    Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
  • January 9, 2024
    A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) ( CheckMate 8HW )
  • January 8, 2024
    Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence
  • December 22, 2023
    Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
  • October 31, 2023
    Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
  • December 8, 2022
    Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer
  • September 19, 2022
    An Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis
  • July 26, 2022
    A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

Discover the Art of Dance

Discover the Art of Dance

Whether you prefer ballet, jazz, or hip hop , we have a class for you.